A Bioavailability Study of ODM-201 Formulations With a Safety and Tolerability Extension Component in Subjects With Metastatic Chemotherapy-naive Castration-resistant Prostate Cancer

Trial Profile

A Bioavailability Study of ODM-201 Formulations With a Safety and Tolerability Extension Component in Subjects With Metastatic Chemotherapy-naive Castration-resistant Prostate Cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Darolutamide (Primary)
  • Indications Prostate cancer
  • Focus Pharmacokinetics
  • Acronyms ARAFOR
  • Sponsors Orion; Orion Pharma
  • Most Recent Events

    • 02 Nov 2017 Planned End Date changed from 1 Jul 2017 to 1 Dec 2018.
    • 22 Sep 2016 Planned End Date changed from 1 Jul 2016 to 1 Jul 2017.
    • 10 May 2016 Results of combined long-term safety and efficacy data from three studies including this study presented at the 111th Annual Meeting of the American Urological Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top